Background: Fatigue is a common and distressing side effect of androgen deprivation therapy (ADT) for prostate cancer. The goal of the current study was to examine the relationship between changes in fatigue following initiation of ADT and single nucleotide polymorphisms (SNPs) in three pro-inflammatory cytokine genes: interleukin-1 beta (IL1B), interleukin-6 (IL6), and tumor necrosis factor alpha (TNFA). Methods: As part of a larger study, men with prostate cancer (n = 53) were recruited prior to initiation of ADT. Fatigue was assessed at recruitment and 6 months after initiation of ADT. DNA was extracted from blood drawn at baseline. Results: Patients with the IL6-174 (rs1800795) G/C or C/C genotype displayed greater increases in fatigue intrusiveness, frequency, and duration than the G/G genotype (p values 60.05), although inclusion of age, race, and baseline depressive symptomatology in the model attenuated these relationships (p values 60.09). Patients with the TNFA-308 (rs1800629) G/A genotype showed greater increases in fatigue severity than the G/G genotype (p = 0.02). IL1B-511 (rs16944) genotype did not significantly predict changes in fatigue (p values >0.46). Patients with higher numbers of variants displayed greater increases in fatigue duration and interference (p values 60.02) than patients with lower numbers of variants. Conclusions: Prostate cancer patients treated with ADT who carry variant alleles of the IL6 and TNFA genes are susceptible to heightened fatigue. These preliminary data lend support for the role of genetic variation in the development of cancer-related fatigue secondary to ADT. Findings are relevant to attempts to develop personalized approaches to cancer treatment.
Introduction
Androgen deprivation therapy (ADT) is indicated for prostate cancer patients with intermediate or high risk of recurrence or local metastasis (National Comphrehensive Cancer Network, 2011) . ADT typically consists of intramuscular injection of luteinizing hormone-releasing hormone agonists (i.e., leuprolide, goserelin), often with bicalutamide, which results in reduction of testosterone to castration levels. Elimination of testosterone slows the growth of prostate cancer. Although multiple randomized trials have demonstrated the effectiveness of ADT in slowing the progression of prostate cancer (Akaza, 2011) , it is associated with a number of side effects including fatigue. Studies show that approximately 40% of men treated with ADT experience clinically-significant fatigue (Kyrdalen et al., 2010; Storey et al., 2011a) . Fatigue is one of the most distressing side effects of cancer treatment and is associated with reduced quality of life (Baker et al., 2005; Storey et al., 2012) . As such, it is important to examine which patients are at greatest risk.
To date, relatively few studies have examined the role of genes in cancer-related fatigue and none to our knowledge have examined genetic variation in fatigue related to receipt of ADT. Available data suggest that cancer-related fatigue may be associated with single nucleotide polymorphisms (SNPs) as well as differential expression in genes involved in the production of pro-inflammatory cytokines. Regarding polymorphisms, results of four studies suggested that SNPs in cytokine genes are predictive of fatigue in human cancers: SNPs of interleukin-1beta (IL1B) and interleukin-6 (IL6) in breast cancer (Collado-Hidalgo et al., 2008) , IL1B in lung cancer (Rausch et al., 2010) , IL6 and tumor necrosis factor alpha (TNFA) in various cancers during radiation treatment (Aouizerat et al., 2009; Miaskowski et al., 2010) . However, evidence is conflicting (Reinertsen et al., 2011) . These data are intriguing and suggest the need for additional studies examining the role of genes in the development of cancer-related fatigue.
